oxybutynin has been researched along with alendronate in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Abe, M; Hayashi, R; Hirai, Y; Kamiyama, F; Katsumi, H; Kusamori, K; Quan, YS; Sakai, R; Sakane, T; Ueda, A; Yamamoto, A | 1 |
| Katsumi, H | 1 |
| Boche, M; Pokharkar, V | 1 |
| Cui, P; Jia, B; Kong, F; Wang, D | 1 |
| Huang, G; Li, B; Ma, Z; Qin, S | 1 |
2 review(s) available for oxybutynin and alendronate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Development of a novel transdermal delivery system of alendronate, a nitrogen containing bisphosphonate, using a new type of hydrophilic patch and dissolving microneedle arrays].
Topics: Alendronate; Animals; Bone Density Conservation Agents; Diphosphonates; Humans; Hydrophobic and Hydrophilic Interactions; Needles; Nitrogen; Transdermal Patch | 2014 |
6 other study(ies) available for oxybutynin and alendronate
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Butylated Hydroxytoluene; Calcium; Female; Growth Plate; Humans; Hypercalcemia; Nitrogen; Osteoporosis; Ovariectomy; Permeability; Rats; Rats, Sprague-Dawley; Rats, Wistar; Skin; Skin Irritancy Tests; Transdermal Patch | 2010 |
Positive effect of alendronate on bone turnover in ovariectomised rats' osteoporosis: comparison of transdermal lipid-based delivery with conventional oral administration.
Topics: Absorptiometry, Photon; Administration, Cutaneous; Administration, Oral; Alendronate; Animals; Bone Density Conservation Agents; Bone Remodeling; Drug Carriers; Emulsions; Female; Osteoporosis; Ovariectomy; Rats; Transdermal Patch; Treatment Outcome | 2018 |
Novel combinatorial transdermal drug delivery of alendronate with risedronate for the treatment of osteoporosis.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Calcium; Drug Delivery Systems; Drug Therapy, Combination; Female; Osteoporosis; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Risedronic Acid; Transdermal Patch | 2019 |
Ultrasound-assisted transdermal delivery of alendronate for the treatment of osteoporosis.
Topics: Administration, Cutaneous; Alendronate; Animals; Biological Availability; Bone Density Conservation Agents; Calcium; Chitosan; Disease Models, Animal; Drug Delivery Systems; Drug Liberation; Male; Nanoparticles; Osteoporosis; Particle Size; Permeability; Rats; Rats, Sprague-Dawley; Skin; Transdermal Patch; Treatment Outcome; Ultrasonic Waves | 2020 |